These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8794312)

  • 1. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate.
    Conley AJ; Kessler JA; Boots LJ; McKenna PM; Schleif WA; Emini EA; Mark GE; Katinger H; Cobb EK; Lunceford SM; Rouse SR; Murthy KK
    J Virol; 1996 Oct; 70(10):6751-8. PubMed ID: 8794312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
    Ruprecht RM; Hofmann-Lehmann R; Smith-Franklin BA; Rasmussen RA; Liska V; Vlasak J; Xu W; Baba TW; Chenine AL; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Montefiori DC; McClure HM
    Transfus Clin Biol; 2001 Aug; 8(4):350-8. PubMed ID: 11642027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
    Parren PW; Marx PA; Hessell AJ; Luckay A; Harouse J; Cheng-Mayer C; Moore JP; Burton DR
    J Virol; 2001 Sep; 75(17):8340-7. PubMed ID: 11483779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.
    Nara PL; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Gallo RC; Fischinger PJ; Goudsmit J
    J Virol; 1990 Aug; 64(8):3779-91. PubMed ID: 2370681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2.
    el-Amad Z; Murthy KK; Higgins K; Cobb EK; Haigwood NL; Levy JA; Steimer KS
    AIDS; 1995 Dec; 9(12):1313-22. PubMed ID: 8605050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
    Neurath AR; Strick N; Lin K; Jiang S
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.
    Gauduin MC; Safrit JT; Weir R; Fung MS; Koup RA
    J Infect Dis; 1995 May; 171(5):1203-9. PubMed ID: 7751695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
    Gauduin MC; Parren PW; Weir R; Barbas CF; Burton DR; Koup RA
    Nat Med; 1997 Dec; 3(12):1389-93. PubMed ID: 9396610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
    Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
    Front Immunol; 2018; 9():244. PubMed ID: 29651286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.
    Gibbs CJ; Peters R; Gravell M; Johnson BK; Jensen FC; Carlo DJ; Salk J
    Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3348-52. PubMed ID: 2014254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.
    Conley AJ; Kessler JA; Boots LJ; Tung JS; Arnold BA; Keller PM; Shaw AR; Emini EA
    Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3348-52. PubMed ID: 7512731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.
    Purtscher M; Trkola A; Gruber G; Buchacher A; Predl R; Steindl F; Tauer C; Berger R; Barrett N; Jungbauer A
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1651-8. PubMed ID: 7888224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.
    Nishimura Y; Igarashi T; Haigwood N; Sadjadpour R; Plishka RJ; Buckler-White A; Shibata R; Martin MA
    J Virol; 2002 Mar; 76(5):2123-30. PubMed ID: 11836389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
    Lockey TD; Slobod KS; Caver TE; D'Costa S; Owens RJ; McClure HM; Compans RW; Hurwitz JL
    Immunol Res; 2000; 21(1):7-21. PubMed ID: 10803879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant.
    Andrus L; Prince AM; Bernal I; McCormack P; Lee DH; Gorny MK; Zolla-Pazner S
    J Infect Dis; 1998 Apr; 177(4):889-97. PubMed ID: 9534960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
    Girard M; Kieny MP; Pinter A; Barre-Sinoussi F; Nara P; Kolbe H; Kusumi K; Chaput A; Reinhart T; Muchmore E
    Proc Natl Acad Sci U S A; 1991 Jan; 88(2):542-6. PubMed ID: 1988952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120.
    Safrit JT; Fung MS; Andrews CA; Braun DG; Sun WN; Chang TW; Koup RA
    AIDS; 1993 Jan; 7(1):15-21. PubMed ID: 7680205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees.
    Bogers WM; Koornstra WH; Dubbes RH; ten Haaft PJ; Verstrepen BE; Jhagjhoorsingh SS; Haaksma AG; Niphuis H; Laman JD; Norley S; Schuitemaker H; Goudsmit J; Hunsmann G; Heeney JL; Wigzell H
    J Gen Virol; 1998 Dec; 79 ( Pt 12)():2895-903. PubMed ID: 9880002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
    Alsmadi O; Tilley SA
    J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.